Psychoendocrinology: arginine vasopressin and resilience in patients with major depressive disorder

Affiliations

01 February 2023

-

doi: 10.1017/S1092852921000730


Abstract

Background: There is a burgeoning body of evidence suggesting that arginine vasopressin (AVP) acts as a neuromodulator of the stress response. AVP stimulates the release of adrenocorticotropic hormone, synergistic to corticotropin-releasing hormone, which might explain AVP's role in resilience. Personal hardiness is the bedrock of resilience. Numerous studies have demonstrated elevated plasma levels of AVP in patients with major depressive disorder (MDD), suggesting an etiopathogenetic role as well as a novel therapeutic target.

Objective: The aim of this study was to examine the relationship between AVP and resilience in patients with MDD and to determine AVP levels in serum of patients with MDD.

Methods: Forty patients with MDD and 40 healthy control subjects were studied using the Dispositional Resilience (Hardiness) Scale by Barton, the Quality of Life Scale, the Social Readjustment Rating Scale, and the Beck Depression Inventory. Biochemical analysis of plasma levels of AVP, using the enzyme-linked immunosorbent assay (ELISA), was performed for all participants.

Results: Levels of AVP were statistically significantly elevated in patients with MDD compared with healthy controls. Psychological hardiness was decreased in patients with MDD compared with healthy controls, a finding also statistically significant. There was a negative correlation between plasma AVP level and psychological hardiness.

Conclusion: AVP and psychological hardiness are negatively correlated, reflecting lower stress resilience. AVP levels are indeed higher in patients struggling with MDD.

Keywords: AVP; MDD; psychological hardiness; resilience; stress.


Similar articles

Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.

Scott LV, Dinan TG.Life Sci. 1998;62(22):1985-98. doi: 10.1016/s0024-3205(98)00027-7.PMID: 9627097 Review.

Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor.

DeBold CR, Sheldon WR, DeCherney GS, Jackson RV, Alexander AN, Vale W, Rivier J, Orth DN.J Clin Invest. 1984 Feb;73(2):533-8. doi: 10.1172/JCI111240.PMID: 6321557 Free PMC article.

Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.

Poretti MB, Sawant RS, Rask-Andersen M, de Cuneo MF, Schiƶth HB, Perez MF, Carlini VP.Psychopharmacology (Berl). 2016 Mar;233(6):1077-86. doi: 10.1007/s00213-015-4187-4. Epub 2015 Dec 23.PMID: 26700241

Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects.

Rubin RT, O'Toole SM, Rhodes ME, Sekula LK, Czambel RK.Psychiatry Res. 1999 Dec 13;89(1):1-20. doi: 10.1016/s0165-1781(99)00085-2.PMID: 10643873 Clinical Trial.

[Role of the neurohypophysis in psychological stress].

Scantamburlo G, Ansseau M, Legros JJ.Encephale. 2001 May-Jun;27(3):245-59.PMID: 11488255 Review. French.


Cited by

Relationship between postpartum depression and plasma vasopressin level at 6-8 weeks postpartum: a cross-sectional study.

Kashkouli M, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A, Saber A, Darvishnia H, Azarbayjani K.Sci Rep. 2023 Mar 2;13(1):3518. doi: 10.1038/s41598-022-27223-6.PMID: 36864065 Free PMC article.


KMEL References